Ethical, medical and legal issues for the use of placebos in future lipid intervention trials

Current Opinion in Lipidology

Volumn 12, Issue 6, 2001, Pages 599-600

  Dujovne, Carlos A ^a,c   Tonkin, Andrew M ^b  

^a Kansas Foundation for Clinical Pharmacology   (United States)

^b NATIONAL HEART FOUNDATION OF AUSTRALIA   (Australia)

^c RADIANT RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID; PLACEBO;

ATHEROSCLEROSIS; CLINICAL PROTOCOL; DYSLIPIDEMIA; EDITORIAL; LEGAL ASPECT; MEDICAL ETHICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT PLANNING;

ADULT; AGED; CLINICAL TRIALS; ETHICS, MEDICAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; RISK FACTORS;

EID: 0035198268     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200112000-00001     Document Type: Editorial

References (2)

1. Expanded clinical evaluation of lovastatin (EXCEL) study: Design and patient characteristics of a double-blind, placebo-controlled study in patients with moderate hypercholesterolemia
2. Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin